Phil, a chemistry teacher, experienced dramatic health improvements with Ozempic until his insurance stopped covering it, forcing him to seek alternatives. As brand-name drugs face shortages and high costs, compounding pharmacies and telehealth companies have stepped in, offering cheaper, unapproved versions. While these alternatives provide relief for some, they exist in a regulatory gray area and raise concerns about safety and efficacy. The growing demand has also led to self-administered treatments and black-market sourcing of active ingredients, especially from overseas. This parallel drug economy is challenging traditional pharmaceutical monopolies and insurance models, highlighting a broader issue of access and affordability in healthcare.